Alnylam Loses RNAi Patent in Europe Analyst Says No Worries: related news

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

Alnylam Loses RNAi Patent in Europe; Analyst Says No Worries

Alnylam Pharmaceuticals (NASDAQ: ALNY) isn’t used to losing patent cases, but it happened yesterday in Europe to one of the company’s RNA interference patents, known as Glover. The company said it plans to appeal.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 10, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

MedMira Awarded China Patent

MedMira Inc. announced that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No. 10/163,675) and the European Union (European Patent No. EP1417489).

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Microsoft Sued Over User Editable Toolbar Patent

If you follow the patent world, you know of Gary Odom, who is known as The Patent Hawk. To say he's a big supporter of the patent system would be something of an understatement. He's been known to comment here on occasion, employing the style seen all-too-often among patent system apologists commenting on Techdirt posts: insult repeatedly and broadly, offer no actual points, refuse to actually counter anything we say, provide absolutely no evidence and (for good measure) insult again. However, as reader Jon has pointed out to us, Odom recently received a new patent (he's got a bunch) on tool group manipulations and he's now suing Microsoft for the way its toolbars work in Office 2007.

Ronaldo-no-no-no-no-no

Cristiano Ronaldo is still itching to move to Real Madrid despite meeting with Alex Ferguson to discuss a possible future at United.

Non-Disruptive Backups and Migrations Enhances European Patent Protection and Management

The European Patent Office grants European patents. The EPO carries out searches and substantive examinations on a steadily rising number of European patent applications and international applications filed under the Patent Cooperation Treaty. The European Patent Office (EPO) needed to support up to 60 million patents documents and 800,000 patents within a high availability and ultra resilient DB2 environment. The European Patent Office deployed BMC DB2 solutions to more effectively support its customers and the management of its patent applications.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,� said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

MedMira Awarded China Patent to Complete IP Triple Crown

HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

MedMira Awarded China Patent to Complete IP Triple Crown

HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

Search took 0.58 seconds.